Deal-Making Darling Among Latest To Retract China NDAs
This article was originally published in PharmAsia News
Very few people doubt about what China FDA can do to reduce its notorious drug approval backlog, the agency's actual moves and impact to the industry, however, is shocking to many. Meanwhile, a rigorous clinical data review has been expanded to Beijing and Shanghai with local FDA involved.
Register for our free email digests: